#1 Clinical Trials Search in Europe

Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

↓

Matched clinical trials

  • Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Denmark France Germany Greece Italy +4

  • Study on Isatuximab, Carfilzomib, and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia Greece Portugal

  • Study Comparing bb2121 with Standard Treatments for Patients with Relapsed and Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Italy The Netherlands Norway +1

  • Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Czechia Denmark France Germany +7

  • Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Denmark France Germany Greece Italy +4

  • Study Comparing Linvoseltamab to Elotuzumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • Study on the Safety and Effectiveness of BCMACP03 for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium The Netherlands

  • Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

    Not recruiting

    1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Greece Italy Norway Portugal

  • Study of isatuximab, belantamab mafodotin and dexamethasone combination for patients with relapsed or refractory multiple myeloma

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Greece Italy Norway